| Dr Paulette L Foster-galbraith, MD | |
|
130 Darran St, Gulfport, MS 39503-3409 | |
| (228) 831-1988 | |
| (228) 832-3844 |
| Full Name | Dr Paulette L Foster-galbraith |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 32 Years |
| Location | 130 Darran St, Gulfport, Mississippi |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215963723 | NPI | - | NPPES |
| 0115339 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 14436 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northern Navajo Medical Center | Shiprock, NM | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dhhs Phs Naihs Shiprock Hospital | 0749193837 | 93 |
News Archive
More research is needed before conclusions can be drawn about the effect of recent reforms on hospital quality, let alone about the merits of the coalition government's proposals to extend competition, warn experts on bmj.com today.
Randomised Controlled Trials (RCTs) are considered the 'gold standard' research method for assessing new medical treatments. But research published in BioMed Central's open access journal Trials shows that the design of a remarkable 93 percent of 2235 so-called RCTs published in some Chinese medical journals during 1994 to 2005 was flawed, casting doubt on the reliability of research that is likely to influence medical decision-makers.
University of British Columbia researchers have developed a specialized microscope that has the potential ability to both diagnose diseases that include skin cancer and perform incredibly precise surgery-all without cutting skin.
Orthovita, Inc. , an orthobiologics and biosurgery company, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Vitoss Bioactive Foam-2X Bone Graft Substitute for use as a non-structural bone void filler for use in the spine, pelvis and extremities. Orthovita expects to launch the newest addition to its bone graft substitute product line by late February or early March of 2011.
An Editorial published in The Lancet today [Friday 16 August] examines recent turmoil in the NHS, accusing the UK government of appearing to treat the NHS as a failing bank or business, based on recent headlines about NHS ‘bailouts' and cost-cutting.
› Verified 1 days ago
| Entity Name | Dhhs Phs Naihs Shiprock Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780639971 PECOS PAC ID: 0749193837 Enrollment ID: O20031105000809 |
News Archive
More research is needed before conclusions can be drawn about the effect of recent reforms on hospital quality, let alone about the merits of the coalition government's proposals to extend competition, warn experts on bmj.com today.
Randomised Controlled Trials (RCTs) are considered the 'gold standard' research method for assessing new medical treatments. But research published in BioMed Central's open access journal Trials shows that the design of a remarkable 93 percent of 2235 so-called RCTs published in some Chinese medical journals during 1994 to 2005 was flawed, casting doubt on the reliability of research that is likely to influence medical decision-makers.
University of British Columbia researchers have developed a specialized microscope that has the potential ability to both diagnose diseases that include skin cancer and perform incredibly precise surgery-all without cutting skin.
Orthovita, Inc. , an orthobiologics and biosurgery company, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Vitoss Bioactive Foam-2X Bone Graft Substitute for use as a non-structural bone void filler for use in the spine, pelvis and extremities. Orthovita expects to launch the newest addition to its bone graft substitute product line by late February or early March of 2011.
An Editorial published in The Lancet today [Friday 16 August] examines recent turmoil in the NHS, accusing the UK government of appearing to treat the NHS as a failing bank or business, based on recent headlines about NHS ‘bailouts' and cost-cutting.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Paulette L Foster-galbraith, MD 130 Darran St, Gulfport, MS 39503-3409 Ph: (228) 831-1988 | Dr Paulette L Foster-galbraith, MD 130 Darran St, Gulfport, MS 39503-3409 Ph: (228) 831-1988 |
News Archive
More research is needed before conclusions can be drawn about the effect of recent reforms on hospital quality, let alone about the merits of the coalition government's proposals to extend competition, warn experts on bmj.com today.
Randomised Controlled Trials (RCTs) are considered the 'gold standard' research method for assessing new medical treatments. But research published in BioMed Central's open access journal Trials shows that the design of a remarkable 93 percent of 2235 so-called RCTs published in some Chinese medical journals during 1994 to 2005 was flawed, casting doubt on the reliability of research that is likely to influence medical decision-makers.
University of British Columbia researchers have developed a specialized microscope that has the potential ability to both diagnose diseases that include skin cancer and perform incredibly precise surgery-all without cutting skin.
Orthovita, Inc. , an orthobiologics and biosurgery company, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Vitoss Bioactive Foam-2X Bone Graft Substitute for use as a non-structural bone void filler for use in the spine, pelvis and extremities. Orthovita expects to launch the newest addition to its bone graft substitute product line by late February or early March of 2011.
An Editorial published in The Lancet today [Friday 16 August] examines recent turmoil in the NHS, accusing the UK government of appearing to treat the NHS as a failing bank or business, based on recent headlines about NHS ‘bailouts' and cost-cutting.
› Verified 1 days ago
Marcus John Wilson, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1110 Broad Ave, Suite 700, Gulfport, MS 39501 Phone: 228-864-0314 Fax: 228-868-8345 | |
Daniel Salmeron, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 14116 Customs Blvd, Gulfport, MS 39503 Phone: 601-957-6300 | |
Dr. Donald D. Weaver, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1612 31st Ave, Gulfport, MS 39501 Phone: 228-864-8454 Fax: 228-865-1457 | |
Taylor Hairston, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 15190 Community Rd, Gulfport, MS 39503 Phone: 228-220-5200 | |
Candace Worsham, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1924 30th Ave, Gulfport, MS 39501 Phone: 228-863-7117 | |
Mitchell Adam Sanford, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 12057 Highway 49 Ste C, Gulfport, MS 39503 Phone: 228-832-9385 Fax: 888-498-3529 |